Lonza
Update in progressLONN.SW (Swiss)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
Lonza Group AG and its subsidiaries supply pharma, biotech and nutrition products and services worldwide. It operates four segments: Biologics, for contract development and manufacturing of drug substances and products; Small Molecules, offering integrated development and manufacturing for drug substances and intermediates; Cell & Gene, developing platforms and providing CDMOs, regulatory support, and cell therapies; Capsules & Health Ingredients, providing capsules, dosage forms and health ingredients.
Company score
- Sentiment
- 1.35
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.41
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.67
- Governance
- 0.47
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.44
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.89
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!